iqvia semaglutide tirzepatide prescriptions us q3 2024 GLP-1 prescription trends through June This Week in GLP-1: Apotex

Patients with a history of gene therapy or hematopoietic stem cell transplantation were excluded.Data were summarized descriptively by genotype, age, and gender

Subsequently another work of the same research team analyzed the metabolic effects of CACT down-expression in human myocyte cells stably transfected with CACT antisense cDNA

Dose Group GI Adverse Events (%) Nausea (%) Abdominal Discomfort/Pain Placebo 32.6% 11.6% Low baseline 1 mg 48.6% ~20% Mild, infrequent 4 mg (escalated) 60.0% ~30% Moderate increase 8 mg (escalated) 57.5% ~38% Present in dose-escalation phase 12 mg (escalated) 66.7% 45.8% Highest incidence, mostly transient Source: Jastreboff AM, Kaplan LM, Fras JP, et al

Pediatr Dermatol 32:536538 Natarajan E (2019) Black and brown oro-facial mucocutaneous neoplasms

MEDVis primary differentiator is speed and convenience